通过LNA gapmeR反义寡核苷酸靶向lncRNA MALAT1抑制蛋白酶体亚基基因表达并触发抗多发性骨髓瘤活性
研究探讨长链非编码RNA MALAT1在多发性骨髓瘤中的功能及可成药性。用LNA-gapmeR反义寡核苷酸靶向MALAT1可在体外和小鼠异种移植模型中抑制骨髓瘤细胞增殖并触发凋亡,并下调蛋白酶体亚基基因转录激活因子NRF1和NRF2、降低蛋白酶体活性、增加多泛素化蛋白积累。
要点
- 靶向MALAT1的LNA-gapmeR反义寡核苷酸在体外和小鼠异种移植模型中均抑制骨髓瘤细胞增殖并触发凋亡。
- MALAT1拮抗下调NRF1和NRF2,降低胰蛋白酶样、糜蛋白酶样和半胱天冬酶样蛋白酶体活性,并导致多泛素化蛋白积累。
- NRF1和NRF2下降源于其负调控因子KEAP1的转录激活,导致抗氧化基因表达降低和活性氧水平升高。
核心结论
- MALAT1在调控蛋白酶体机器中起关键作用,靶向MALAT1是多发性骨髓瘤治疗的新强力选择(原文为概念验证)。
研究设计与样本
- 研究采用LNA-gapmeR反义寡核苷酸靶向MALAT1,在体外和小鼠人骨髓瘤异种移植模型中评估其对多发性骨髓瘤细胞的功能影响和可成药性。
主要发现
- 靶向MALAT1的LNA-gapmeR反义寡核苷酸在体外和小鼠人骨髓瘤异种移植模型中均拮抗骨髓瘤细胞增殖并触发凋亡。
- MALAT1拮抗下调蛋白酶体亚基基因的两个主要转录激活因子NRF1和NRF2,并导致胰蛋白酶样、糜蛋白酶样和半胱天冬酶样蛋白酶体活性降低及多泛素化蛋白积累。
- NRF1和NRF2下降源于其负调控因子KEAP1的转录激活,并导致抗氧化基因表达降低和活性氧水平升高。
- NRF1促进MALAT1表达,形成正反馈环路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) are still to be investigated. Here, we studied the functional significance and the druggability of the oncogenic lncRNA MALAT1 in MM. Targeting MALAT1 by novel LNA-gapmeR antisense oligonucleotide antagonized MM cell proliferation and triggered apoptosis both in vitro and in vivo in a murine xenograft model of human MM. Of note, antagonism of MALAT1 downmodulated the two major transcriptional activators of proteasome subunit genes, namely NRF1 and NRF2, and resulted in reduced trypsin, chymotrypsin and caspase-like proteasome activities and in accumulation of polyubiquitinated proteins. NRF1 and NRF2 decrease upon MALAT1 targeting was due to transcriptional activation of their negative regulator KEAP1, and resulted in reduced expression of anti-oxidant genes and increased ROS levels. In turn, NRF1 promoted MALAT1 expression thus establishing a positive feedback loop. Our findings demonstrate a crucial role of MALAT1 in the regulation of the proteasome machinery, and provide proof-of-concept that its targeting is a novel powerful option for the treatment of MM.
引用
- Amodio N, Stamato MA, Juli G, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018. PMID: 29487387. doi:10.1038/s41375-018-0067-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。